Cargando…

Current and Future Pathways in Aspergillus Diagnosis

Aspergillus fumigatus has been designated by the World Health Organization as a critical priority fungal pathogen. Some commercially available diagnostics for many forms of aspergillosis rely on fungal metabolites. These encompass intracellular molecules, cell wall components, and extracellular secr...

Descripción completa

Detalles Bibliográficos
Autores principales: Dobiáš, Radim, Stevens, David A., Havlíček, Vladimír
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9952630/
https://www.ncbi.nlm.nih.gov/pubmed/36830296
http://dx.doi.org/10.3390/antibiotics12020385
_version_ 1784893679429746688
author Dobiáš, Radim
Stevens, David A.
Havlíček, Vladimír
author_facet Dobiáš, Radim
Stevens, David A.
Havlíček, Vladimír
author_sort Dobiáš, Radim
collection PubMed
description Aspergillus fumigatus has been designated by the World Health Organization as a critical priority fungal pathogen. Some commercially available diagnostics for many forms of aspergillosis rely on fungal metabolites. These encompass intracellular molecules, cell wall components, and extracellular secretomes. This review summarizes the shortcomings of antibody tests compared to tests of fungal products in body fluids and highlights the application of β-d-glucan, galactomannan, and pentraxin 3 in bronchoalveolar lavage fluids. We also discuss the detection of nucleic acids and next-generation sequencing, along with newer studies on Aspergillus metallophores.
format Online
Article
Text
id pubmed-9952630
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99526302023-02-25 Current and Future Pathways in Aspergillus Diagnosis Dobiáš, Radim Stevens, David A. Havlíček, Vladimír Antibiotics (Basel) Review Aspergillus fumigatus has been designated by the World Health Organization as a critical priority fungal pathogen. Some commercially available diagnostics for many forms of aspergillosis rely on fungal metabolites. These encompass intracellular molecules, cell wall components, and extracellular secretomes. This review summarizes the shortcomings of antibody tests compared to tests of fungal products in body fluids and highlights the application of β-d-glucan, galactomannan, and pentraxin 3 in bronchoalveolar lavage fluids. We also discuss the detection of nucleic acids and next-generation sequencing, along with newer studies on Aspergillus metallophores. MDPI 2023-02-13 /pmc/articles/PMC9952630/ /pubmed/36830296 http://dx.doi.org/10.3390/antibiotics12020385 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Dobiáš, Radim
Stevens, David A.
Havlíček, Vladimír
Current and Future Pathways in Aspergillus Diagnosis
title Current and Future Pathways in Aspergillus Diagnosis
title_full Current and Future Pathways in Aspergillus Diagnosis
title_fullStr Current and Future Pathways in Aspergillus Diagnosis
title_full_unstemmed Current and Future Pathways in Aspergillus Diagnosis
title_short Current and Future Pathways in Aspergillus Diagnosis
title_sort current and future pathways in aspergillus diagnosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9952630/
https://www.ncbi.nlm.nih.gov/pubmed/36830296
http://dx.doi.org/10.3390/antibiotics12020385
work_keys_str_mv AT dobiasradim currentandfuturepathwaysinaspergillusdiagnosis
AT stevensdavida currentandfuturepathwaysinaspergillusdiagnosis
AT havlicekvladimir currentandfuturepathwaysinaspergillusdiagnosis